Medical Device Success, Inc.

Episode 71 Strategic Planning Part 1 for Companies and Individuals

Only 23% of companies follow a formal strategic planning process. Companies with strategic plans are 12% more profitable. The big MedTech companies are in the final phases of the 2022 strategic plans. What about the small to medium sized companies? What about you as an individual? Imagine how much more productive and profitable you might be with your own personal plan. This is part 1 of a 2-part series to offer some guidance on creating a strategic plan whether it is for a company, a function or you as an individual. Today we will cover Assumptions, the SWOT analysis, Opportunities and Gaps and finally Key Goals and Objectives. In part 2, I will cover strategies and tactics and executing the plan. This is important because only 13% of companies successfully execute their annual plan.

I will be using slides. For podcast listeners, I will try to clearly explain my progress through the slides. There is a way you can get copies of the slides. You have heard me talk about the MedTech Leaders community. This is where MedTech professionals get together to help each other out with best practices, problems, solutions and ideas. You can learn more at medtechleaders dot net. Members of the MTL community can request a free copy of the slides. There is a very low annual fee and there is a free trial. It costs less than 4 Starbuck’s coffees. Why charge anything you ask? To keep the spammers out and cover basic community costs. I guarantee you I am not making money from the community. It is more of a passion project than a profit project at this point.

Now Go Win Your Week!

Podcast Link https://bit.ly/30PNb4S

Episode 71 Strategic Planning Part 1 for Companies and Individuals - Medical Device Success - Ideas You Can Put To Work Today! Only 23% of companies follow a formal strategic planning process. Companies with strategic plans are 12% more profitable. The big MedTech companies are in the final phases of the 2022 strategic plans. What about the small to medium companies? What about you as an individual? Imagine how much more pr...

Episode 70 - In the C-Suite with Patricia Zilliox, CEO, Eyevensys
"Instead, they turn a little muscle in the eye into a protein factory."

Today’s guest is Patricia Zilliox, CEO of Eyevensys, a clinical stage biotechnology company based in Paris, France and Dallas, Texas. Patricia is running a very exciting startup that combines a medical device and gene-therapy that is targeting some of the biggest causes of blindness. The idea behind this biotechnology is the brainchild of Founder Francine Behar-Cohen, MD, PhD. What I find fascinating is the fact that they do not use a virus to transport the therapy. Instead, they turn a little muscle in the eye into a protein factory. There are advantages to this approach that you will learn about in a few minutes. We will talk about the technology, Patricia’s career and some of the early challenges in being in her first CEO role.

For those of you looking for a community of like-minded MedTech professionals, consider looking at the MedTech Leaders community. I am the host of this community. You can learn more at medtechleaders dot net. One advantage of being in the community is that most of these podcasts/video casts start out as live events. Members can attend and ask questions. And I am working on events related to AI in MedTech, Value Based Care, Telehealth and of course more C-Suite interviews.

Now Go Win Your Week!!

Podcast link – https://bit.ly/3ngn2Vf

Episode 70 - In the C-Suite with Patricia Zilliox, CEO, Eyevensys - Medical Device Success - Ideas You Can Put To Work Today! Today’s guest is Patricia Zilliox, CEO of Eyevensys, a clinical stage biotechnology company based in Paris, France and Dallas, Texas. Patricia is running a very exciting startup that combines a medical device and gene-therapy that is targeting some of the biggest causes of blindness. The idea behi...

Episode 66 – Game Changing Subcategories and Storytelling in MedTech with David Aaker, PhD
“It is a big fallacy that your audience is rational”
Our guest today is David Aaker, PhD, considered by some to be the Father of Modern Branding. In this episode we are talking about creating game changing subcategories and storytelling in high tech and MedTech. Dave is Professor Emeritus at Stanford University and is the Vice Chairman of the consulting firm Prophet. He has written numerous best-selling books on branding, marketing, leadership and now story telling. A couple weeks ago we talked to Geoffrey Moore about moving through the Technology Adoption Life Cycle. Today we add another layer of sophistication to this with the concept of creating a game changing subcategory for your product to help separate it from the competition and thrive. To support this effort, we also spend some time on story telling as a tactic to support your brand. Think about it, as an individual, when you share a story about yourself with friends or colleagues, you are probably hoping to enhance your personal brand. How you do this and what you include or leave out may make all the difference. The same can work for the products you make or represent.

As always, you will find links to Dave, Prophet and some of his books in the show notes. And, again, you will hear me refer to a couple attendees from the MedTech Leaders community. You can learn more about this community at MedTechleaders net.

By the way, I recorded Dave while on the road in a hotel room. Yes…I have to do some field work too. So, the audio and video may not up to my usual quality level. I appreciate your patience with this.

Now Go Win Your Week!

Podcast Link - https://bit.ly/3n6cdUk

Episode 66 – Game Changing Subcategories and Storytelling in MedTech with David Aaker, PhD - Medical Device Success - Ideas You Can Put To Work Today! “It is a big fallacy that your audience is rational”. Our guest today is David Aaker, PhD, considered by some to be the Father of Modern Branding. In this episode we are talking about creating game changing subcategories and storytelling in high tech and medtech. Dave is professor emeritus at St...